All In Biotech

Drug Trial Radar · NCT07486895

Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects

An Open-label, Randomized, Crossover Trial in Healthy Subjects to Assess Dose Strength Equivalence Among 164.4 and 328.8 mg Strengths of Oral Centanafadine QD XR Capsules

Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Mar 8, 2023

Primary completion

May 18, 2023

Study completion May 18, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult participants.

Conditions

  • Healthy Adult Participants

Interventions

  • CentanafadineDrug

    Centanafadine will be administered as an oral capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of CentanafadineTime frame: Up to Day 5
  2. Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of CentanafadineTime frame: Up to Day 5
  3. Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinfinity) of CentanafadineTime frame: Up to Day 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON plc

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.